- Home
- CWK vs ICUI Comparison
CWK vs ICUI Comparison
Compare CWK & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWK
- ICUI
- Stock Information
- Founded
- CWK 1784
- ICUI 1984
- Country
- CWK United States
- ICUI United States
- Employees
- CWK N/A
- ICUI N/A
- Industry
- CWK Real Estate
- ICUI Medical/Dental Instruments
- Sector
- CWK Finance
- ICUI Health Care
- Exchange
- CWK Nasdaq
- ICUI Nasdaq
- Market Cap
- CWK 3.9B
- ICUI 3.2B
- IPO Year
- CWK 2018
- ICUI 1992
- Fundamental
- Price
- CWK $15.94
- ICUI $143.21
- Analyst Decision
- CWK Buy
- ICUI Buy
- Analyst Count
- CWK 7
- ICUI 6
- Target Price
- CWK $17.50
- ICUI $183.60
- AVG Volume (30 Days)
- CWK 1.9M
- ICUI 300.1K
- Earning Date
- CWK 10-30-2025
- ICUI 11-06-2025
- Dividend Yield
- CWK N/A
- ICUI N/A
- EPS Growth
- CWK 152.30
- ICUI N/A
- EPS
- CWK 0.95
- ICUI N/A
- Revenue
- CWK $10,003,900,000.00
- ICUI $2,320,363,000.00
- Revenue This Year
- CWK $7.96
- ICUI N/A
- Revenue Next Year
- CWK $5.10
- ICUI N/A
- P/E Ratio
- CWK $16.89
- ICUI N/A
- Revenue Growth
- CWK 6.77
- ICUI N/A
- 52 Week Low
- CWK $7.64
- ICUI $107.00
- 52 Week High
- CWK $17.33
- ICUI $175.51
- Technical
- Relative Strength Index (RSI)
- CWK 54.74
- ICUI 68.04
- Support Level
- CWK $14.71
- ICUI $131.99
- Resistance Level
- CWK $16.37
- ICUI $138.48
- Average True Range (ATR)
- CWK 0.55
- ICUI 5.82
- MACD
- CWK -0.05
- ICUI 0.40
- Stochastic Oscillator
- CWK 78.91
- ICUI 80.41
About CWK Cushman & Wakefield plc
Cushman & Wakefield is one of the largest commercial real estate services firms in the world, with global headquarters in Chicago. The firm provides various real estate-related services to owners, occupiers, and investors. These include brokerage services for leasing and capital markets sales as well as advisory services such as valuation, project management, and facilities management.
About ICUI ICU Medical Inc.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.